MFDS Approves 'Voxzogoju' Treatment for Pediatric Achondroplasia

The Ministry of Food and Drug Safety announced on the 31st that it has approved the rare drug 'Voxzogoju (generic name Bhosoritide)' 0.4mg·0.56mg·1.2mg for the treatment of achondroplasia in children aged 4 months or older whose growth plates have not yet closed.

Achondroplasia is a genetic bone growth disorder caused by a mutation in the gene regulating the proliferation and differentiation of chondrocytes, the 'fibroblast growth factor receptor 3 (FGFR-3)'.

Voxzogoju is a therapeutic agent that inhibits the overactivated FGFR-3 signaling in pediatric patients with achondroplasia, inducing the proliferation and differentiation of chondrocytes and thereby promoting bone formation within the cartilage. Until now, there has been no treatment for pediatric achondroplasia patients.

The Ministry of Food and Drug Safety explained that after designating this drug as the 10th product under the 'Global Innovative Fast Track (GIFT)' system in July last year, it conducted a rapid review to facilitate its swift introduction into domestic medical practice.

An official from the Ministry stated, "Voxzogoju will provide new treatment opportunities for pediatric patients with achondroplasia," and added, "We will continue to ensure that new treatments are promptly supplied to patients with rare and intractable diseases, expanding their treatment opportunities."

This content was produced with the assistance of AI translation services.